Vera Therapeutics, Inc. (VERA): who owns it and who trades it
As of Nov 16, 2026, VERA insiders reported 24 open-market sales worth $8.6M and 1 purchase worth $250K in the last 12 months, with 66% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marshall Fordyce (CEO), with $6.4M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vera Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VERA
219 funds and institutions reported VERA shares worth $3.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.75M | 8.01% | $247M | +13% |
| Avoro Capital Advisors LLC | 5.72M | 7.97% | $246M | -3% |
| State Street Corp | 4.15M | 5.78% | $178M | +23% |
| T. Rowe Price Associates | 4.01M | 5.59% | $172M | -12% |
| Deep Track Capital, LP | 4.00M | 5.57% | $172M | -3% |
| Deerfield Management Company, L.P. | 3.92M | 5.46% | $168M | +5% |
| Kynam Capital Management, LP | 2.89M | 4.03% | $124M | -15% |
| Morgan Stanley | 2.80M | 3.90% | $120M | +659% |
| Sofinnova Investments, Inc. | 2.79M | 3.89% | $120M | No change |
| FMR LLC (Fidelity) | 2.77M | 3.86% | $119M | +4% |
| Vanguard Capital Management LLC | 2.76M | 3.84% | $118M | +3% |
| Eversept Partners, LP | 2.21M | 3.08% | $94.9M | +2% |
| Logos Global Management LP | 2.20M | 3.06% | $94.4M | – |
| California State Teachers Retirement System | 2.07M | 2.89% | $48.4M | +4072% |
| Integral Health Asset Management, LLC | 1.75M | 2.44% | $75.1M | +9% |
| Bellevue Group AG | 1.71M | 2.38% | $73.4M | No change |
| Geode Capital Management, LLC | 1.69M | 2.36% | $72.6M | +8% |
| Alliancebernstein L.P. | 1.59M | 2.22% | $64M | +21% |
| Goldman Sachs Group Inc | 1.38M | 1.92% | $59.3M | +22% |
| Frontier Capital Management Co LLC | 1.30M | 1.80% | $55.6M | +135% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VERA insiders reported $250K of open-market purchases and $8.6M of sales. 66% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Marshall Fordyce | CEO | Sale plan | 18,500 | $37.00 | $684K | Form 4 |
| Sep 2, 2026 | Marshall Fordyce | CEO | Sale plan | 18,500 | $35.12 | $650K | Form 4 |
| Jul 7, 2026 | Marshall Fordyce | CEO | Sale plan | 1,000 | $40.78 | $40.8K | Form 4 |
| Jul 7, 2026 | Marshall Fordyce | CEO | Sale plan | 2,200 | $43.59 | $95.9K | Form 4 |
| Jul 7, 2026 | Marshall Fordyce | CEO | Sale plan | 10,500 | $42.86 | $450K | Form 4 |
| Jul 7, 2026 | Marshall Fordyce | CEO | Sale plan | 32,550 | $42.07 | $1.4M | Form 4 |
| Jun 23, 2026 | Marshall Fordyce | CEO | Sale plan | 18,412 | $37.93 | $698K | Form 4 |
| Jun 23, 2026 | Marshall Fordyce | CEO | Sale plan | 88 | $38.43 | $3.4K | Form 4 |
| May 12, 2026 | Marshall Fordyce | CEO | Sale plan | 14,219 | $36.64 | $521K | Form 4 |
| May 12, 2026 | Marshall Fordyce | CEO | Sale plan | 4,281 | $37.09 | $159K | Form 4 |
| Apr 14, 2026 | Marshall Fordyce | CEO | Sale plan | 14,130 | $43.66 | $617K | Form 4 |
| Apr 14, 2026 | Marshall Fordyce | CEO | Sale plan | 900 | $45.51 | $41K | Form 4 |
| Apr 14, 2026 | Marshall Fordyce | CEO | Sale plan | 7,921 | $44.58 | $353K | Form 4 |
| Feb 23, 2026 | Robert Brenner | Chief Medical Officer | Sale | 2,151 | $41.98 | $90.3K | Form 4 |
| Feb 23, 2026 | Joseph R Young | Vice president | Sale | 3,117 | $41.98 | $131K | Form 4 |
| Feb 23, 2026 | Sean Grant | CFO | Sale | 4,949 | $41.98 | $208K | Form 4 |
| Feb 23, 2026 | Marshall Fordyce | CEO | Sale | 16,925 | $41.98 | $711K | Form 4 |
| Feb 23, 2026 | David Lee Johnson | Chief Operating Officer | Sale | 2,579 | $41.98 | $108K | Form 4 |
| Feb 23, 2026 | William D. Turner | Chief Regulatory Officer | Sale | 2,187 | $41.98 | $91.8K | Form 4 |
| Feb 23, 2026 | Laurence Matthew Skelton | Chief Commercial Officer | Sale | 1,582 | $41.98 | $66.4K | Form 4 |
| Dec 15, 2025 | William D. Turner | Chief Regulatory Officer | Sale | 10,000 | $50.08 | $501K | Form 4 |
| Dec 11, 2025 | Patrick G Enright | Director | Purchase | 5,882 | $42.50 | $250K | Form 4 |
| Dec 8, 2025 | William D. Turner | Chief Regulatory Officer | Sale | 10,000 | $45.31 | $453K | Form 4 |
| Dec 3, 2025 | William D. Turner | Chief Regulatory Officer | Sale | 10,000 | $40.00 | $400K | Form 4 |
| Nov 21, 2025 | Jason S Carter | Chief Legal Officer | Sale | 3,864 | $27.82 | $107K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO, Director | – | $6.4M | Sep 15, 2026 |
| William D. Turner | Chief Regulatory Officer | – | $1.4M | Feb 23, 2026 |
| Patrick G Enright | Director | $250K | – | Dec 11, 2025 |
| Sean Grant | CHIEF FINANCIAL OFFICER | – | $208K | Feb 23, 2026 |
| Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | – | $131K | Feb 23, 2026 |
| David Lee Johnson | Chief Operating Officer | – | $108K | Feb 23, 2026 |
| Jason S Carter | Chief Legal Officer | – | $107K | Nov 21, 2025 |
| Robert Brenner | Chief Medical Officer | – | $90.3K | Feb 23, 2026 |
| Laurence Matthew Skelton | Chief Commercial Officer | – | $66.4K | Feb 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VERA short interest
High short interest. 16.8% of VERA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.14M VERA shares were sold short, 16.8% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 1.43M shares, buying them all back would take about 8.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.14M | 16.79% | -11% | 1.43M | 8.5 |
| Oct 15, 2026 | 13.59M | 18.85% | -21% | 1.90M | 7.2 |
| Sep 30, 2026 | 17.24M | 23.92% | +1% | 2.21M | 7.8 |
| Sep 15, 2026 | 17.04M | 23.64% | -14% | 2.76M | 6.2 |
| Aug 31, 2026 | 19.87M | 27.58% | +18% | 1.84M | 10.8 |
| Aug 14, 2026 | 16.81M | 23.33% | +10% | 2.42M | 7.0 |
| Jul 31, 2026 | 15.28M | 21.21% | +1% | 1.62M | 9.4 |
| Jul 15, 2026 | 15.08M | 21.01% | +12% | 3.02M | 5.0 |
| Jun 30, 2026 | 13.52M | 18.84% | +14% | 2.30M | 5.9 |
| Jun 15, 2026 | 11.84M | 16.49% | +9% | 1.14M | 10.4 |
| May 29, 2026 | 10.83M | 15.09% | +7% | 969,229 | 11.2 |
| May 15, 2026 | 10.08M | 14.04% | +7% | 1.01M | 10.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Vera Therapeutics company events
Vera Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 15, 2026AnnouncementAs noted in Item 7.01, on September 15, 2026, the Company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgAN at risk for disease progression. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 9, 2026LeadershipVera Therapeutics, Inc. announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026. Filing
- Jul 7, 2026AnnouncementVera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Filing
- Jun 2, 2026AnnouncementVera Therapeutics, Inc. issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. Filing
- May 26, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 9, 2026LeadershipThe board of directors of Vera Therapeutics, Inc. appointed Christopher Hite to the Board, effective immediately. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 18, 2025LeadershipVera Therapeutics, Inc. announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025. Filing
- Dec 10, 2025AnnouncementVera Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of… Filing
- Nov 26, 2025LeadershipThe board of directors of Vera Therapeutics, Inc. appointed James R. Meyers to the Board, effective immediately. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Vera Therapeutics financials
Famous investors that hold VERA
2 of the 50 well-known investors we track reported holding VERA in their latest 13F filing. The largest position is Israel Englander's, worth $27.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 838,290 | $27.1M | 0.0% | +201% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 24,775 | $800K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named VERA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G/A | 7.8% |
| Nov 16, 2026 | Deep Track Capital, LP | 13G/A | 9.7% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 3.8% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 3.8% |
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G/A | 7.8% |
| Nov 16, 2026 | Deep Track Capital, LP | 13G/A | 9.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.6% |
Questions about Vera Therapeutics, Inc. (VERA) stock
Who owns the most VERA stock?
The largest reported owner of Vera Therapeutics, Inc. (VERA) is BlackRock, Inc., with 8.0% of the company. In total, 219 funds and institutions reported holding VERA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are VERA insiders buying or selling?
In the last 12 months, VERA insiders reported 1 open-market purchase worth $250K and 24 sales worth $8.6M. The latest trade was on Sep 15, 2026. See every trade.
What is the short interest in VERA?
As of Oct 30, 2026, 12.14M VERA shares were sold short, 16.8% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 1.43M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.
Which famous investors hold VERA?
2 of the 50 well-known investors we track reported VERA in their latest 13F filing, including Israel Englander, Paul Tudor Jones. The largest position is worth $27.1M. See all holders.
Executive pay
Vera Therapeutics's chief executive was paid a total of $7M for the year ended Dec 31, 2025, up 24% from $5.6M the year before. In the last 12 months, Vera Therapeutics's executives and directors bought $250K of stock on the open market and sold $8.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.